Eurofins Expands North American Footprint with $400M Element…

Event summary

Eurofins completed the $400M acquisition of Element’s North American Life Sciences Testing Services business on October 1, 2026.
The deal adds 27 labs, 750 employees, and $150M in annual revenue to Eurofins’ North American operations.
The acquired business offers Biopharma, Environmental, and Food testing services, filling gaps in Eurofins’ U.S. and Canadian coverage.
Eurofins plans to integrate the labs into its existing hub-and-spoke network to improve economies of scale.

The big picture

Eurofins’ acquisition of Element’s North American testing business strengthens its position in a fragmented market, addressing historical underrepresentation in key regions. The deal aligns with broader industry trends of consolidation among testing service providers, as firms seek scale to meet increasing regulatory demands and client expectations for faster, more accurate results. With $400M in enterprise value, the acquisition underscores Eurofins’ commitment to expanding its geographic and service reach in the life sciences sector.

What we're watching

Integration Challenges: How Eurofins will manage the seamless integration of 27 new labs into its existing network without disrupting service continuity.
Market Consolidation: Whether this acquisition signals further consolidation in the North American life sciences testing market.
Revenue Synergies: The pace at which Eurofins can leverage cross-selling opportunities between the acquired business and its broader service portfolio.